Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ICLR 
ICON PLC (ICLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: ICLR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $211.73
1 Year Target Price $211.73
| 11 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.77% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.98B USD | Price to earnings Ratio 24.26 | 1Y Target Price 211.73 |
Price to earnings Ratio 24.26 | 1Y Target Price 211.73 | ||
Volume (30-day avg) 17 | Beta 1.23 | 52 Weeks Range 125.10 - 234.60 | Updated Date 10/23/2025 |
52 Weeks Range 125.10 - 234.60 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-22 | When - | Estimate 3.32 | Actual 3.31 |
Profitability
Profit Margin 9.82% | Operating Margin (TTM) 12.83% |
Management Effectiveness
Return on Assets (TTM) 4.35% | Return on Equity (TTM) 8.3% |
Valuation
Trailing PE 24.26 | Forward PE 13.53 | Enterprise Value 18163477204 | Price to Sales(TTM) 1.85 |
Enterprise Value 18163477204 | Price to Sales(TTM) 1.85 | ||
Enterprise Value to Revenue 2.25 | Enterprise Value to EBITDA 13.23 | Shares Outstanding 76359932 | Shares Floating 76795312 |
Shares Outstanding 76359932 | Shares Floating 76795312 | ||
Percent Insiders 0.65 | Percent Institutions 102.12 |
Upturn AI SWOT
ICON PLC
Company Overview
History and Background
ICON PLC, founded in 1990, is a global provider of outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, and medical device companies. It has grown through organic expansion and strategic acquisitions.
Core Business Areas
- Clinical Research Services: Provides comprehensive clinical trial management services from Phase I to Phase IV, including study design, site selection, patient recruitment, data management, and regulatory submissions.
- Laboratory Services: Offers central laboratory services, bioanalytical services, and biomarker services to support clinical trials.
- Commercialisation & Outcomes: Provides strategic consultancy and commercialization support.
- Strategic Solutions: Offers specialized expertise in areas such as medical imaging, patient-reported outcomes, and adaptive trial designs.
Leadership and Structure
ICON PLC is led by a board of directors and an executive leadership team. The organizational structure includes functional departments and regional teams to serve global clients.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: End-to-end management of clinical trials across various therapeutic areas. This is a core service. Competitors include IQVIA, Labcorp, and PPD. Difficult to quantify market share in a meaningful way as it varies greatly by specific service and therapeutic area.
- Central Laboratories: Central lab services to support clinical trials for pharmaceutical and biotech companies. Competitors include Labcorp, Quest Diagnostics, and Syneos Health. Difficult to quantify market share in a meaningful way as it varies greatly by specific service and therapeutic area.
- Bioanalytical and Biomarker Services: Quantitative analysis of drugs, metabolites, and biomarkers in biological samples.Competitors include Labcorp, Quest Diagnostics, and Syneos Health. Difficult to quantify market share in a meaningful way as it varies greatly by specific service and therapeutic area.
Market Dynamics
Industry Overview
The clinical research organization (CRO) industry is experiencing growth driven by increasing R&D spending by pharmaceutical and biotechnology companies, rising complexity of clinical trials, and the need for outsourcing expertise.
Positioning
ICON PLC is a leading global CRO, known for its full-service capabilities, global reach, and technological innovation.
Total Addressable Market (TAM)
The global CRO market is projected to reach hundreds of billions of dollars. ICON PLC is well-positioned to capture a significant share due to its full-service offering and global presence.
Upturn SWOT Analysis
Strengths
- Global Presence
- Comprehensive Service Offering
- Strong Track Record
- Technological Innovation
- Experienced Management Team
Weaknesses
- High Client Concentration
- Exposure to Regulatory Changes
- Integration Risks from Acquisitions
- Competitive Landscape
Opportunities
- Increasing R&D Spending by Pharma
- Growing Complexity of Clinical Trials
- Expansion into Emerging Markets
- Adoption of Digital Technologies
Threats
- Economic Downturn
- Pricing Pressure
- Competition from Larger CROs
- Regulatory Changes
Competitors and Market Share
Key Competitors
- IQVIA (IQV)
- Labcorp (LH)
- Syneos Health (SYNH)
Competitive Landscape
ICON PLC competes with larger CROs based on service capabilities, geographic reach, and price. It aims to differentiate itself through technological innovation and customer service.
Major Acquisitions
PRA Health Sciences
- Year: 2021
- Acquisition Price (USD millions): 12000
- Strategic Rationale: Expanded ICON's global presence, service capabilities, and client base.
Growth Trajectory and Initiatives
Historical Growth: ICON PLC has experienced consistent revenue growth driven by organic expansion and acquisitions.
Future Projections: Analyst estimates suggest continued revenue growth driven by favorable industry trends.
Recent Initiatives: Recent initiatives include investments in digital technologies, expansion into new geographies, and strategic acquisitions.
Summary
ICON PLC is a strong player in the CRO industry, benefitting from increasing pharmaceutical R&D spending and the growing complexity of clinical trials. Its global reach and comprehensive service offering are key strengths. It needs to watch out for economic downturns, regulatory changes, and competition from larger CROs. Its financial health depends on efficient management and successful integration of acquisitions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ICON PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1998-05-15 | CEO & Director Mr. Barry Balfe | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 39900 | Website https://www.iconplc.com |
Full time employees 39900 | Website https://www.iconplc.com | ||
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.